{
    "clinical_study": {
        "@rank": "111115", 
        "arm_group": {
            "arm_group_label": "Health Services Research (PET/CT scan)", 
            "description": "Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies positron emission tomography (PET)/computed tomography\n      (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or\n      cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging\n      procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are\n      present in the lung and compare the results with the pre-therapy imaging."
        }, 
        "brief_title": "Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT", 
        "condition": [
            "Advanced Adult Primary Liver Cancer", 
            "Liver Metastases", 
            "Localized Unresectable Adult Primary Liver Cancer", 
            "Recurrent Adult Primary Liver Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Liver Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To estimate the absolute difference in post-therapy Yttrium-90 microsphere\n      hepatopulmonary shunt fraction and the pre-therapy Technetium-99m macroaggregated albumin\n      hepatopulmonary shunt fraction in patients with unresectable primary hepatic malignancy and\n      hepatic metastatic disease.\n\n      SECONDARY OBJECTIVES:\n\n      I. To quantify and compare the pre-therapy Technetium-99m macroaggregated albumin particle\n      sizes and post-therapy Yttrium-90 microsphere sizes.\n\n      OUTLINE:\n\n      Patients receive routine pre-therapy Technetium-99m macroaggregated albumin. Patients then\n      undergo routine radioembolization with Yttrium-90 microspheres. Within 36 hours after\n      radioembolization, patients undergo PET/CT imaging.\n\n      Available imaging, clinical, interventional and surgical follow-up data for 2 years after\n      completion of enrollment in the study will be obtained."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who undergo intra-arterial hepatic 99mTc MAA evaluation in anticipation of\n             90Y microsphere radioembolization\n\n        Exclusion Criteria:\n\n          -  Patients who are unable to give consent\n\n          -  Prisoners"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The target population includes patients with unresectable liver metastases or malignancy\n        who are referred to The Ohio State University Wexner Medical Center for Yttrium-90\n        microsphere radioembolization therapy."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119065", 
            "org_study_id": "OSU-13176", 
            "secondary_id": "NCI-2014-00278"
        }, 
        "intervention": [
            {
                "arm_group_label": "Health Services Research (PET/CT scan)", 
                "description": "Undergo PET/CT scan", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PET", 
                    "PET scan", 
                    "tomography, positron emission"
                ]
            }, 
            {
                "arm_group_label": "Health Services Research (PET/CT scan)", 
                "description": "Undergo PET/CT scan", 
                "intervention_name": "computed tomography", 
                "intervention_type": "Procedure", 
                "other_name": "tomography, computed"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Yttrium-90 Radioembolization", 
            "hepatic malignancy", 
            "hepatic metastatic disease"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "link": {
            "description": "The Jamesline", 
            "url": "http://cancer.osu.edu"
        }, 
        "location": {
            "contact": {
                "email": "Chadwick.Wright@osumc.edu", 
                "last_name": "Chadwick L. Wright", 
                "phone": "614-293-8315"
            }, 
            "contact_backup": {
                "email": "bonnie.williams@osumc.edu", 
                "last_name": "Bonnie Willams", 
                "phone": "614-293-6237"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center"
            }, 
            "investigator": {
                "last_name": "Chadwick L. Wright", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization", 
        "overall_contact": {
            "email": "Jamesline@osumc.edu", 
            "last_name": "Ohio State University Comprehensive Cancer Cancer", 
            "phone": "1-800-293-5066"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University Comprehensive Cancer Center", 
            "last_name": "Chadwick Wright", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Non-parametric Wilcoxon signed rank testing will be used to compare the 99mTc MAA and 90Y microsphere shunt fractions. Alternatively, a natural log transformation of the hepatopulmonary shunt fractions may be used to normalize these data for subsequent parametric paired t-test analysis.", 
            "measure": "Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values", 
            "safety_issue": "No", 
            "time_frame": "Baseline to up to 36 hours after radioembolization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119065"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ohio State University Comprehensive Cancer Center", 
            "investigator_full_name": "Chadwick Wright", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Descriptive statistical assessment of Technetium-99m macroaggregated albumin particle size and microsphere size for each patient (e.g., mean, median, standard deviation, distribution, etc.) will be performed.", 
            "measure": "In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to 24 months"
        }, 
        "source": "Ohio State University Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ohio State University Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}